{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:15:30Z","timestamp":1772770530577,"version":"3.50.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["Canada Graduate Scholarship"],"award-info":[{"award-number":["Canada Graduate Scholarship"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["COVID-19 Operating Grant OV3-170649"],"award-info":[{"award-number":["COVID-19 Operating Grant OV3-170649"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["Foundation Grant"],"award-info":[{"award-number":["Foundation Grant"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Emergent Ventures\/Thistledown Foundation FAST grant"},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"crossref","award":["Medicine by Design"],"award-info":[{"award-number":["Medicine by Design"]}],"id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"crossref","award":["Ontario Graduate Scholarship"],"award-info":[{"award-number":["Ontario Graduate Scholarship"]}],"id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"crossref"}]},{"name":"panCELLa Inc."},{"name":"Emergent Ventures\/The Mercatus Center FAST","award":["#2161"],"award-info":[{"award-number":["#2161"]}]},{"name":"Emergent Ventures\/The Mercatus Center FAST","award":["#2189"],"award-info":[{"award-number":["#2189"]}]},{"name":"Temerty Foundation Knowledge Translation Grant-Novel Antibody Tools for COVID-19"},{"name":"Canada Foundation for Innovation Infrastructure and Operating Grant","award":["#IOF-33363"],"award-info":[{"award-number":["#IOF-33363"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Immunologically impaired individuals respond poorly to vaccines, highlighting the need for additional strategies to protect these vulnerable populations from COVID-19. While monoclonal antibodies (mAbs) have emerged as promising tools to manage infectious diseases, the transient lifespan of neutralizing mAbs in patients limits their ability to confer lasting, passive prophylaxis from SARS-CoV-2. Here, we attempted to solve this problem by combining cell and mAb engineering in a way that provides durable immune protection against viral infection using safe and universal cell therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Mouse embryonic stem cells equipped with our FailSafe\u2122 and induced allogeneic cell tolerance technologies were engineered to express factors that potently neutralize SARS-CoV-2, which we call \u2018neutralizing biologics\u2019 (nBios). We subcutaneously transplanted the transgenic cells into mice and longitudinally assessed the ability of the cells to deliver nBios into circulation. To do so, we quantified plasma nBio concentrations and SARS-CoV-2 neutralizing activity over time in transplant recipients. Finally, using similar cell engineering strategies, we genetically modified FailSafe\u2122 human-induced pluripotent stem cells to express SARS-CoV-2 nBios.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Transgenic mouse embryonic stem cells engineered for safety and allogeneic-acceptance can secrete functional and potent SARS-CoV-2 nBios. As a dormant, subcutaneous tissue, the transgenic cells and their differentiated derivatives long-term deliver a supply of protective nBio titers in vivo. Moving toward clinical relevance, we also show that human-induced pluripotent stem cells, similarly engineered for safety, can secrete highly potent nBios.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Together, these findings show the promise and potential of using \u2018off-the-shelf\u2019 cell products that secrete neutralizing antibodies for sustained protective immunity against current and future viral pathogens of public health significance.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13287-023-03556-5","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T18:02:12Z","timestamp":1699293732000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cell-based passive immunization for protection against SARS-CoV-2 infection"],"prefix":"10.1186","volume":"14","author":[{"given":"Evan","family":"Sawula","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane","family":"Miersch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric D.","family":"Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengjin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang-Yu","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Kit","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Saberianfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Harding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachdev S.","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4311-0413","authenticated-orcid":false,"given":"Andras","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,6]]},"reference":[{"key":"3556_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1056\/NEJMc2104974","volume":"385","author":"LJ Abu-Raddad","year":"2021","unstructured":"Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med. 2021;385:187\u20139.","journal-title":"N Engl J Med"},{"key":"3556_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41564-021-01053-0","volume":"7","author":"S Nasreen","year":"2022","unstructured":"Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, et al. Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. Nat Microbiol. 2022;7:379\u201385.","journal-title":"Nat Microbiol"},{"key":"3556_CR3","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1056\/NEJMoa2106599","volume":"385","author":"T Pilishvili","year":"2021","unstructured":"Pilishvili T, Gierke R, Fleming-Dutra KE, Farrar JL, Mohr NM, Talan DA, et al. Effectiveness of mRNA Covid-19 vaccine among U.S. Health care personnel. N Engl J Med. 2021;385:e90.","journal-title":"N Engl J Med"},{"key":"3556_CR4","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","volume":"398","author":"SY Tartof","year":"2021","unstructured":"Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398:1407\u201316.","journal-title":"Lancet"},{"key":"3556_CR5","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386:1532\u201346.","journal-title":"N Engl J Med"},{"key":"3556_CR6","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","volume":"602","author":"L Liu","year":"2022","unstructured":"Liu L, Iketani S, Guo Y, Chan JF-W, Wang M, Liu L, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022;602:676\u201381.","journal-title":"Nature"},{"key":"3556_CR7","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","volume":"385","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med. 2021;385:585\u201394.","journal-title":"N Engl J Med"},{"key":"3556_CR8","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","volume":"21","author":"JS Tregoning","year":"2021","unstructured":"Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21:626\u201336.","journal-title":"Nat Rev Immunol"},{"key":"3556_CR9","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41591-022-01753-y","volume":"28","author":"HF Tseng","year":"2022","unstructured":"Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and delta variants. Nat Med. 2022;28:1063\u201371.","journal-title":"Nat Med"},{"key":"3556_CR10","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","volume":"608","author":"Y Cao","year":"2022","unstructured":"Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608:593\u2013602.","journal-title":"Nature"},{"key":"3556_CR11","first-page":"521","volume":"614","author":"Y Cao","year":"2022","unstructured":"Cao Y, Jian F, Wang J, Yu Y, Song W, Yisimayi A, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. 2022;614:521\u20139.","journal-title":"Nature"},{"key":"3556_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.chom.2022.11.012","volume":"31","author":"P Qu","year":"2023","unstructured":"Qu P, Evans JP, Faraone JN, Zheng Y-M, Carlin C, Anghelina M, et al. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. Cell Host Microbe. 2023;31:9-17.e3.","journal-title":"Cell Host Microbe"},{"key":"3556_CR13","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","volume":"185","author":"A Tuekprakhon","year":"2022","unstructured":"Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, Zhou D, Ginn HM, Selvaraj M, et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA1 serum. Cell. 2022;185:2422-2433.e13.","journal-title":"Cell"},{"key":"3556_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41586-022-05053-w","volume":"608","author":"Q Wang","year":"2022","unstructured":"Wang Q, Guo Y, Iketani S, Nair MS, Li Z, Mohri H, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature. 2022;608:603\u20138.","journal-title":"Nature"},{"key":"3556_CR15","doi-asserted-by":"publisher","first-page":"ofa353","DOI":"10.1093\/ofid\/ofab353","volume":"8","author":"ME Agha","year":"2021","unstructured":"Agha ME, Blake M, Chilleo C, Wells A, Haidar G. Suboptimal response to coronavirus disease 2019 messenger RNA vaccines in patients with hematologic malignancies: a need for vigilance in the postmasking era. Open Forum Infect Dis. 2021;8:ofa353.","journal-title":"Open Forum Infect Dis"},{"key":"3556_CR16","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.kint.2021.03.014","volume":"99","author":"I Benotmane","year":"2021","unstructured":"Benotmane I, Gautier-Vargas G, Cognard N, Olagne J, Heibel F, Braun-Parvez L, et al. Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. Kidney Int. 2021;99:1487\u20139.","journal-title":"Kidney Int"},{"key":"3556_CR17","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1001\/jama.2021.7489","volume":"325","author":"BJ Boyarsky","year":"2021","unstructured":"Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325:2204\u20136.","journal-title":"JAMA"},{"key":"3556_CR18","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.2215\/CJN.03500321","volume":"16","author":"A Grupper","year":"2021","unstructured":"Grupper A, Sharon N, Finn T, Cohen R, Israel M, Agbaria A, et al. Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol. 2021;16:1037\u201342.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3556_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1001\/jamaoncol.2021.5437","volume":"8","author":"MJ Mair","year":"2022","unstructured":"Mair MJ, Berger JM, Berghoff AS, Starzer AM, Ortmayr G, Puhr HC, et al. Humoral immune response in hematooncological patients and health care workers who received SARS-CoV-2 vaccinations. JAMA Oncol. 2022;8:106\u201313.","journal-title":"JAMA Oncol"},{"key":"3556_CR20","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","volume":"22","author":"L Monin","year":"2021","unstructured":"Monin L, Laing AG, Mu\u00f1oz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22:765\u201378.","journal-title":"Lancet Oncol"},{"key":"3556_CR21","doi-asserted-by":"publisher","first-page":"eabf1906","DOI":"10.1126\/scitranslmed.abf1906","volume":"13","author":"BE Jones","year":"2021","unstructured":"Jones BE, Brown-Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec TP, et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Transl Med. 2021;13:eabf1906.","journal-title":"Sci Transl Med"},{"key":"3556_CR22","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","volume":"584","author":"L Liu","year":"2020","unstructured":"Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020;584:450\u20136.","journal-title":"Nature"},{"key":"3556_CR23","doi-asserted-by":"publisher","first-page":"167177","DOI":"10.1016\/j.jmb.2021.167177","volume":"433","author":"S Miersch","year":"2021","unstructured":"Miersch S, Li Z, Saberianfar R, Ustav M, Brett Case J, Blazer L, et al. Tetravalent SARS-CoV-2 neutralizing antibodies show enhanced potency and resistance to escape mutations. J Mol Biol. 2021;433:167177.","journal-title":"J Mol Biol"},{"key":"3556_CR24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto D, Park Y-J, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583:290\u20135.","journal-title":"Nature"},{"key":"3556_CR25","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.abf4830","volume":"371","author":"CG Rappazzo","year":"2021","unstructured":"Rappazzo CG, Tse LV, Kaku CI, Wrapp D, Sakharkar M, Huang D, et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science. 2021;371:823\u20139.","journal-title":"Science"},{"key":"3556_CR26","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1126\/science.abc7520","volume":"369","author":"TF Rogers","year":"2020","unstructured":"Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He W-T, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369:956\u201363.","journal-title":"Science"},{"key":"3556_CR27","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1126\/science.abc7424","volume":"369","author":"AZ Wec","year":"2020","unstructured":"Wec AZ, Wrapp D, Herbert AS, Maurer DP, Haslwanter D, Sakharkar M, et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science. 2020;369:731\u20136.","journal-title":"Science"},{"key":"3556_CR28","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","volume":"584","author":"SJ Zost","year":"2020","unstructured":"Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020;584:443\u20139.","journal-title":"Nature"},{"key":"3556_CR29","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","volume":"385","author":"M Dougan","year":"2021","unstructured":"Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med. 2021;385:1382\u201392.","journal-title":"N Engl J Med"},{"key":"3556_CR30","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","volume":"385","author":"A Gupta","year":"2021","unstructured":"Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385:1941\u201350.","journal-title":"N Engl J Med"},{"key":"3556_CR31","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","volume":"386","author":"MJ Levin","year":"2022","unstructured":"Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, et al. Intramuscular AZD7442 (Tixagevimab\u2013Cilgavimab) for prevention of Covid-19. N Engl J Med. 2022;386:2188\u2013200.","journal-title":"N Engl J Med"},{"key":"3556_CR32","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa2035002","volume":"384","author":"DM Weinreich","year":"2021","unstructured":"Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384:238\u201351.","journal-title":"N Engl J Med"},{"key":"3556_CR33","doi-asserted-by":"publisher","first-page":"110812","DOI":"10.1016\/j.celrep.2022.110812","volume":"39","author":"K Westendorf","year":"2022","unstructured":"Westendorf K, \u017dentelis S, Wang L, Foster D, Vaillancourt P, Wiggin M, et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 2022;39:110812.","journal-title":"Cell Rep"},{"key":"3556_CR34","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","volume":"385","author":"MP O\u2019Brien","year":"2021","unstructured":"O\u2019Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan K-C, Sarkar N, et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N Engl J Med. 2021;385:1184\u201395.","journal-title":"N Engl J Med"},{"key":"3556_CR35","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJMoa1608368","volume":"376","author":"M Mandai","year":"2017","unstructured":"Mandai M, Watanabe A, Kurimoto Y, Hirami Y, Morinaga C, Daimon T, et al. Autologous induced stem-cell-derived retinal cells for macular degeneration. N Engl J Med. 2017;376:1038\u201346.","journal-title":"N Engl J Med"},{"key":"3556_CR36","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jacc.2017.11.042","volume":"71","author":"LW Miller","year":"2018","unstructured":"Miller LW. Trial of embryonic stem cell-derived cardiac progenitor cells: an encouraging start. J Am Coll Cardiol. 2018;71:439\u201342.","journal-title":"J Am Coll Cardiol"},{"key":"3556_CR37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0140-6736(14)61376-3","volume":"385","author":"SD Schwartz","year":"2015","unstructured":"Schwartz SD, Regillo CD, Lam BL, Eliott D, Rosenfeld PJ, Gregori NZ, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt\u2019s macular dystrophy: follow-up of two open-label phase 1\/2 studies. Lancet. 2015;385:509\u201316.","journal-title":"Lancet"},{"key":"3556_CR38","doi-asserted-by":"publisher","first-page":"e2022091118","DOI":"10.1073\/pnas.2022091118","volume":"118","author":"T Deuse","year":"2021","unstructured":"Deuse T, Tediashvili G, Hu X, Gravina A, Tamenang A, Wang D, et al. Hypoimmune induced pluripotent stem cell-derived cell therapeutics treat cardiovascular and pulmonary diseases in immunocompetent allogeneic mice. Proc Natl Acad Sci U S A. 2021;118:e2022091118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3556_CR39","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41587-019-0016-3","volume":"37","author":"T Deuse","year":"2019","unstructured":"Deuse T, Hu X, Gravina A, Wang D, Tediashvili G, De C, et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nat Biotechnol. 2019;37:252\u20138.","journal-title":"Nat Biotechnol"},{"key":"3556_CR40","unstructured":"Harding J, Vintersten-Nagy K, Yang H, Tang JK, Shutova M, et al. Engineering cells that form immune-privileged tissues and can survive in allogeneic, immune competent hosts. Nat Biomed Eng. In press."},{"key":"3556_CR41","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41577-019-0200-1","volume":"19","author":"R Lanza","year":"2019","unstructured":"Lanza R, Russell DW, Nagy A. Engineering universal cells that evade immune detection. Nat Rev Immunol. 2019;19:723\u201333.","journal-title":"Nat Rev Immunol"},{"key":"3556_CR42","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41586-018-0733-7","volume":"563","author":"Q Liang","year":"2018","unstructured":"Liang Q, Monetti C, Shutova MV, Neely EJ, Hacibekiroglu S, Yang H, et al. Linking a cell-division gene and a suicide gene to define and improve cell therapy safety. Nature. 2018;563:701\u20134.","journal-title":"Nature"},{"key":"3556_CR43","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41551-021-00730-z","volume":"5","author":"B Wang","year":"2021","unstructured":"Wang B, Iriguchi S, Waseda M, Ueda N, Ueda T, Xu H, et al. Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells. Nat Biomed Eng. 2021;5:429\u201340.","journal-title":"Nat Biomed Eng"},{"key":"3556_CR44","doi-asserted-by":"publisher","first-page":"e11260","DOI":"10.1371\/journal.pone.0011260","volume":"5","author":"M Gertsenstein","year":"2010","unstructured":"Gertsenstein M, Nutter LMJ, Reid T, Pereira M, Stanford WL, Rossant J, et al. Efficient generation of germ line transmitting chimeras from C57BL\/6N ES cells by aggregation with outbred host embryos. PLoS ONE. 2010;5:e11260.","journal-title":"PLoS ONE"},{"key":"3556_CR45","doi-asserted-by":"publisher","unstructured":"Talevi A, Bellera CL. One-compartment pharmacokinetic model. The ADME encyclopedia: A comprehensive guide on biopharmacy and pharmacokinetics. Cham: Springer International Publishing; 2021. p. 1\u20138. https:\/\/doi.org\/10.1007\/978-3-030-51519-5_58-1","DOI":"10.1007\/978-3-030-51519-5_58-1"},{"key":"3556_CR46","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/157488408783329931","volume":"3","author":"D Lev\u00eaque","year":"2008","unstructured":"Lev\u00eaque D, Gigou L, Bergerat JP. Clinical pharmacology of trastuzumab. Curr Clin Pharmacol. 2008;3:51\u20135.","journal-title":"Curr Clin Pharmacol"},{"key":"3556_CR47","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/cpt.2459","volume":"111","author":"E Chigutsa","year":"2022","unstructured":"Chigutsa E, Jordie E, Riggs M, Nirula A, Elmokadem A, Knab T, et al. A quantitative modeling and simulation framework to support candidate and dose selection of anti-SARS-CoV-2 monoclonal antibodies to advance bamlanivimab into a first-in-human clinical trial. Clin Pharmacol Ther. 2022;111:595\u2013604.","journal-title":"Clin Pharmacol Ther"},{"key":"3556_CR48","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1002\/cpt.2420","volume":"110","author":"E Chigutsa","year":"2021","unstructured":"Chigutsa E, O\u2019Brien L, Ferguson-Sells L, Long A, Chien J. Population pharmacokinetics and pharmacodynamics of the neutralizing antibodies bamlanivimab and etesevimab in patients with mild to moderate COVID-19 infection. Clin Pharmacol Ther. 2021;110:1302\u201310.","journal-title":"Clin Pharmacol Ther"},{"key":"3556_CR49","doi-asserted-by":"publisher","first-page":"28046","DOI":"10.1073\/pnas.2016093117","volume":"117","author":"A Glasgow","year":"2020","unstructured":"Glasgow A, Glasgow J, Limonta D, Solomon P, Lui I, Zhang Y, et al. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. Proc Natl Acad Sci U S A. 2020;117:28046\u201355.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3556_CR50","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","volume":"181","author":"V Monteil","year":"2020","unstructured":"Monteil V, Kwon H, Prado P, Hagelkr\u00fcys A, Wimmer RA, Stahl M, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181:905-913.e7.","journal-title":"Cell"},{"key":"3556_CR51","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.cell.2005.07.013","volume":"122","author":"S Ding","year":"2005","unstructured":"Ding S, Wu X, Li G, Han M, Zhuang Y, Xu T. Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell. 2005;122:473\u201383.","journal-title":"Cell"},{"key":"3556_CR52","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0378-1119(91)90434-D","volume":"108","author":"H Niwa","year":"1991","unstructured":"Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991;108:193\u20139.","journal-title":"Gene"},{"issue":"12","key":"3556_CR53","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1111\/ajt.17128","volume":"22","author":"A Al Jurdi","year":"2022","unstructured":"Al Jurdi A, Morena L, Cote M, Bethea E, Azzi J, Riella LV. Tixagevimab\/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave. Am J Transplant. 2022;22(12):3130\u20136.","journal-title":"Am J Transplant"},{"key":"3556_CR54","doi-asserted-by":"publisher","first-page":"e458","DOI":"10.1016\/S2665-9913(22)00099-6","volume":"4","author":"T Goulenok","year":"2022","unstructured":"Goulenok T, Delaval L, Delory N, Fran\u00e7ois C, Papo T, Descamps D, et al. Pre-exposure anti-SARS-CoV-2 monoclonal antibodies in severely immunocompromised patients with immune-mediated inflammatory diseases. Lancet Rheumatol. 2022;4:e458\u201361.","journal-title":"Lancet Rheumatol"},{"key":"3556_CR55","doi-asserted-by":"publisher","DOI":"10.1101\/2022.05.24.22275467","author":"AH Karaba","year":"2022","unstructured":"Karaba AH, Kim JD, Chiang TP-Y, Alejo JL, Abedon AT, Mitchell J, et al. Omicron BA.1 and BA.2 neutralizing activity following pre-exposure prophylaxis with Tixagevimab plus Cilgavimab in Vaccinated solid organ transplant recipients. medRxiv. 2022. https:\/\/doi.org\/10.1101\/2022.05.24.22275467.","journal-title":"medRxiv"},{"key":"3556_CR56","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.cell.2021.02.026","volume":"184","author":"ES Winkler","year":"2021","unstructured":"Winkler ES, Gilchuk P, Yu J, Bailey AL, Chen RE, Chong Z, et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell. 2021;184:1804-1820.e16.","journal-title":"Cell"},{"key":"3556_CR57","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jinf.2021.09.013","volume":"84","author":"C Dimeglio","year":"2022","unstructured":"Dimeglio C, Herin F, Martin-Blondel G, Miedoug\u00e9 M, Izopet J. Antibody titers and protection against a SARS-CoV-2 infection. J Infect. 2022;84:248\u201388.","journal-title":"J Infect"},{"key":"3556_CR58","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205\u201311.","journal-title":"Nat Med"},{"key":"3556_CR59","doi-asserted-by":"publisher","first-page":"eadg2783","DOI":"10.1126\/scitranslmed.adg2783","volume":"15","author":"P Schmidt","year":"2023","unstructured":"Schmidt P, Narayan K, Li Y, Kaku CI, Brown ME, Champney E, et al. Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers. Sci Transl Med. 2023;15:eadg2783.","journal-title":"Sci Transl Med"},{"key":"3556_CR60","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000336051","volume":"33","author":"M Eriksdotter-J\u00f6nhagen","year":"2012","unstructured":"Eriksdotter-J\u00f6nhagen M, Linderoth B, Lind G, Aladellie L, Almkvist O, Andreasen N, et al. Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer\u2019s disease. Dement Geriatr Cogn Disord. 2012;33:18\u201328.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"3556_CR61","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1158\/1078-0432.CCR-13-1415","volume":"20","author":"Q Li","year":"2014","unstructured":"Li Q, Wijesekera O, Salas SJ, Wang JY, Zhu M, Aprhys C, et al. Mesenchymal stem cells from human fat engineered to secrete BMP4 are nononcogenic, suppress brain cancer, and prolong survival. Clin Cancer Res. 2014;20:2375\u201387.","journal-title":"Clin Cancer Res"},{"key":"3556_CR62","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1182\/bloodadvances.2017007914","volume":"3","author":"RB Lyde","year":"2019","unstructured":"Lyde RB, Ahn HS, Vo KK, Jarocha DJ, Tkaczynski J, Treffeisen E, et al. Infused factor VIII-expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A. Blood Adv. 2019;3:1368\u201378.","journal-title":"Blood Adv"},{"key":"3556_CR63","doi-asserted-by":"publisher","first-page":"eabm1032","DOI":"10.1126\/sciadv.abm1032","volume":"8","author":"AM Nash","year":"2022","unstructured":"Nash AM, Jarvis MI, Aghlara-Fotovat S, Mukherjee S, Hernandez A, Hecht AD, et al. Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors. Sci Adv. 2022;8:eabm1032.","journal-title":"Sci Adv"},{"key":"3556_CR64","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/nm917","volume":"9","author":"E Hammarlund","year":"2003","unstructured":"Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med. 2003;9:1131\u20137.","journal-title":"Nat Med"},{"key":"3556_CR65","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/40540","volume":"388","author":"RA Manz","year":"1997","unstructured":"Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. Nature. 1997;388:133\u20134.","journal-title":"Nature"},{"key":"3556_CR66","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1074-7613(00)80541-5","volume":"8","author":"MK Slifka","year":"1998","unstructured":"Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity. 1998;8:363\u201372.","journal-title":"Immunity"},{"key":"3556_CR67","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.exer.2013.09.003","volume":"123","author":"S Fuhrmann","year":"2014","unstructured":"Fuhrmann S, Zou C, Levine EM. Retinal pigment epithelium development, plasticity, and tissue homeostasis. Exp Eye Res. 2014;123:141\u201350.","journal-title":"Exp Eye Res"},{"key":"3556_CR68","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nature06902","volume":"453","author":"KL Spalding","year":"2008","unstructured":"Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O, et al. Dynamics of fat cell turnover in humans. Nature. 2008;453:783\u20137.","journal-title":"Nature"},{"key":"3556_CR69","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/cpt.2405","volume":"110","author":"P Chen","year":"2021","unstructured":"Chen P, Datta G, Grace Li Y, Chien J, Price K, Chigutsa E, et al. First-in-human study of bamlanivimab in a randomized trial of hospitalized patients with COVID-19. Clin Pharmacol Ther. 2021;110:1467\u201377.","journal-title":"Clin Pharmacol Ther"},{"key":"3556_CR70","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3390\/v13071202","volume":"13","author":"AC Drouin","year":"2021","unstructured":"Drouin AC, Theberge MW, Liu SY, Smither AR, Flaherty SM, Zeller M, et al. Successful clearance of 300 day SARS-CoV-2 infection in a subject with B-cell depletion associated prolonged (B-DEAP) COVID by REGEN-COV anti-spike monoclonal antibody cocktail. Viruses. 2021;13:1202.","journal-title":"Viruses"},{"key":"3556_CR71","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.3201\/eid2710.211538","volume":"27","author":"D Focosi","year":"2021","unstructured":"Focosi D, Novazzi F, Genoni A, Dentali F, Gasperina DD, Baj A, et al. Emergence of SARS-COV-2 spike protein escape mutation Q493R after treatment for COVID-19. Emerg Infect Dis. 2021;27:2728\u201331.","journal-title":"Emerg Infect Dis"},{"key":"3556_CR72","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMc2202861","volume":"386","author":"EM Scherer","year":"2022","unstructured":"Scherer EM, Babiker A, Adelman MW, Allman B, Key A, Kleinhenz JM, et al. SARS-CoV-2 evolution and immune escape in immunocompromised patients. N Engl J Med. 2022;386:2436\u20138.","journal-title":"N Engl J Med"},{"key":"3556_CR73","doi-asserted-by":"publisher","first-page":"110905","DOI":"10.1016\/j.celrep.2022.110905","volume":"39","author":"S Miersch","year":"2022","unstructured":"Miersch S, Sharma N, Saberianfar R, Chen C, Caccuri F, Zani A, et al. Ultrapotent and broad neutralization of SARS-CoV-2 variants by modular, tetravalent, bi-paratopic antibodies. Cell Rep. 2022;39:110905.","journal-title":"Cell Rep"},{"key":"3556_CR74","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602:657\u201363.","journal-title":"Nature"},{"key":"3556_CR75","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1021\/acschembio.2c00411","volume":"17","author":"JM Labriola","year":"2022","unstructured":"Labriola JM, Miersch S, Chen G, Chen C, Pavlenco A, Saberianfar R, et al. Peptide-antibody fusions engineered by phage display exhibit an ultrapotent and broad neutralization of SARS-CoV-2 variants. ACS Chem Biol. 2022;17:1978\u201388.","journal-title":"ACS Chem Biol"},{"issue":"76","key":"3556_CR76","doi-asserted-by":"publisher","first-page":"eadd5446","DOI":"10.1126\/sciimmunol.add5446","volume":"7","author":"S Luo","year":"2022","unstructured":"Luo S, Zhang J, Kreutzberger AJB, Eaton A, Edwards RJ, Jing C, et al. An antibody from single human VH-rearranging mouse neutralizes all SARS-CoV-2 variants through BA.5 by inhibiting membrane fusion. Sci Immunol. 2022;7(76):eadd5446.","journal-title":"Sci Immunol"},{"key":"3556_CR77","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.chom.2022.10.010","volume":"31","author":"C Dacon","year":"2023","unstructured":"Dacon C, Peng L, Lin T-H, Tucker C, Lee C-CD, Cong Y, et al. Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses. Cell Host Microbe. 2023;31:97\u2013111-e12.","journal-title":"Cell Host Microbe"},{"key":"3556_CR78","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1126\/science.abj3321","volume":"373","author":"D Pinto","year":"2021","unstructured":"Pinto D, Sauer MM, Czudnochowski N, Low JS, Tortorici MA, Housley MP, et al. Broad betacoronavirus neutralization by a stem helix-specific human antibody. Science. 2021;373:1109\u201316.","journal-title":"Science"},{"key":"3556_CR79","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1038\/s41467-021-24013-y","volume":"12","author":"Y Higuchi","year":"2021","unstructured":"Higuchi Y, Suzuki T, Arimori T, Ikemura N, Mihara E, Kirita Y, et al. Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2. Nat Commun. 2021;12:3802.","journal-title":"Nat Commun"},{"key":"3556_CR80","doi-asserted-by":"publisher","first-page":"eabn7737","DOI":"10.1126\/scitranslmed.abn7737","volume":"14","author":"N Ikemura","year":"2022","unstructured":"Ikemura N, Taminishi S, Inaba T, Arimori T, Motooka D, Katoh K, et al. An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo. Sci Transl Med. 2022;14:eabn7737.","journal-title":"Sci Transl Med"},{"key":"3556_CR81","doi-asserted-by":"publisher","first-page":"104935","DOI":"10.1016\/j.isci.2022.104935","volume":"25","author":"AE Chaouat","year":"2022","unstructured":"Chaouat AE, Brizic I, Kucan Brlic P, Atari N, Kliker L, Alfi O, et al. Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern. iScience. 2022;25:104935.","journal-title":"iScience"},{"key":"3556_CR82","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.1038\/s41467-021-25331-x","volume":"12","author":"Y Du","year":"2021","unstructured":"Du Y, Shi R, Zhang Y, Duan X, Li L, Zhang J, et al. A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants. Nat Commun. 2021;12:5000.","journal-title":"Nat Commun"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-023-03556-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-023-03556-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-023-03556-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T19:04:16Z","timestamp":1699297456000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-023-03556-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3556"],"URL":"https:\/\/doi.org\/10.1186\/s13287-023-03556-5","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,6]]},"assertion":[{"value":"20 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were performed in compliance with the Animals for Research Act of Ontario and the Guidelines of the Canadian Council on Animal Care. The protocols performed in this study were approved by the Toronto Centre for Phenogenomics Animal Care Committee under the project \u2018Feasibility Assessment of Cell-Mediated Passive Immunization Against Foreign Pathogens\u2019 (AUP #24-0365H, approved on 18 Nov 2020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.N. is a co-founder of panCELLa Inc. that has exclusive licences for the FailSafe\u2122 and iACT technologies developed by the Nagy lab. A.N. is an inventor of these technologies, and J.H. is an inventor of the iACT technology. All other authors have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"318"}}